Published in
Nature Research, Nature Reviews Clinical Oncology, 8(12), p. 439-440, 2015
DOI: 10.1038/nrclinonc.2015.118
Links
Tools
Combined immunotherapy—a new standard in metastatic melanoma?
Journal article published in 2015 by
Axel Hauschild,
Claus Garbe 
This paper was not found in any repository; the policy of its publisher is unknown or unclear.
Full text: Unavailable
Published version:
archiving forbidden
Data provided by 
Abstract
The efficacy of immunotherapy in metastatic melanoma is established, with anti-CTLA-4 and anti-PD-1 antibody-based therapies providing unexpectedly high responses and prolonged survival. The combination of nivolumab and ipilimumab is now poised to become the new standard of care, based on a 61% response rate in a recent randomized extended phase I/II trial, confirmed by phase III data presented at ASCO 2015.